Latest Regulatory Approval News

Sunshine Metals has reported strong progress at its Queensland projects, highlighted by high-grade drilling results at Liontown, acquisition and planned upgrade of the Mt Moss processing facility, and a strategic divestment of Hodgkinson. The company bolsters its cash position through a $22 million capital raise to fund development and exploration.

Brightstar Resources has greenlit full-scale construction of its Goldfields Project with all key approvals in place, targeting first gold in mid-2027 while boosting its Sandstone resource base to 2.9 million ounces.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

Connected Minerals has secured shareholder and regulatory approvals to acquire Frontier Group, gaining an 80% stake in Angola’s Bailundo Carbonatite Project with expanded mineral rights including niobium and rare earths. Completion is imminent as exploration activities ramp up.

Oceana Metals has validated extensive high-grade rare earth mineralisation at its Serra Negra project in Brazil, underpinning a major drilling campaign backed by a $20 million capital raise.

Aeris Resources has lifted its Group Mineral Resources by 24% and Ore Reserves by 50% to 61Mt and 21Mt respectively, driven by the Peel Mining acquisition and exploration success across its portfolio.

Red Sky Energy has kicked off site works for a Santos-operated drilling campaign at the Innamincka Dome, secured $5.1 million in capital raising, and reported $1.045 million in production receipts for the June quarter.

Barton Gold has delivered another batch of strong assay results from its Phase 2 drilling at the Tunkillia Gold Project, reinforcing the economic potential of Area 223 and advancing its Pre-Feasibility Study towards a Q1 2027 finish.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.